ArticlePloS one2025
Adjuvantation of Kyasanur Forest Disease vaccine with TLR9 agonist CpG adjuvant enhances immunological efficacy and potency of the vaccine.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was carried out with the objectives of formulation of Kyasanur Forest Disease (KFD) vaccine adjuvanted with TLR9 agonist, CpG; evaluation of cell mediated and humoral immune response of CpG adjuvanted KFD vaccine in mice. The KFD seed virus (P9605) procured from ICMR-National Institute of Virology, Pune was used for the preparation of KFD vaccine and was confirmed by Real Time Reverse Transcription-PCR. The KFD vaccine prepared in chick embryo fibroblast primary culture was inactivated with 0.1% of formalin. Safety test was performed to assess the safe does of CpG adjuvant in mice. The KFD vaccine adjuvanted with 10 µg of CpG per dose of vaccine was formulated and immunologically evaluated in mice. Evaluation of humoral immune response (HIR) by mouse protection test showed that CpG when used as an adjuvant, significantly (P < 0.0001) enhances HIR in mice with better survival percentages when compared to the non-adjuvanted KFD vaccine. The cell mediated immune response/cytokine response evaluated by quantifying Interferon-ϒ (IFN-ϒ), Tumour Necrosis Factor-Alpha (TNF-α) and IL-12 production using ELISA showed that CpG significantly (P < 0.001) increases IFN-ϒ, TNF- α and IL-12 when used as an adjuvant in KFD vaccine in mice. The potency test showed that CpG adjuvanted vaccine has higher protective efficacy with better protective index compared with the non-adjuvanted KFD vaccine. Taken together these findings, the study recommends CpG as an adjuvant in the formalin inactivated KFD vaccine since the adjuvantation was safe and enhanced KFD specific immunogenicity and protective efficacy in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.